Ipsen Gets CHMP Nod for Cabometyx in Neuroendocrine Tumors
June 20, 2025
European Commission decision expected Q3 2025 Ipsen that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued